GenesisCare and PreludeDx™ Partner to Provide Access to Ground-Breaking Precision Medicine Test for Women With Early-Stage Breast Cancer
on February 23 2021 9:00 PM
SYDNEY & LAGUNA HILLS, Calif. (BUSINESS WIRE) #breastcancerawareness GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx
TM), a leader in molecular diagnostics and precision medicine, today announced a new strategic partnership aimed at increasing access to personalized breast cancer treatment and improved patient outcomes.
DCISionRT
® is a precision medicine test for women diagnosed with DCIS (Ductal Carcinoma in situ) or Stage 0 breast cancer who are treated with breast-conserving surgery. The DCISionRT test, developed by PreludeDx, assesses a woman’s 10-year risk of recurrence of DCIS or development of invasive breast cancer. The test provides predictive information regarding recurrence risk, allowing physicians to better select those patients who will benefi
MP Peta Murphy on living with terminal breast cancer mamamia.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mamamia.com.au Daily Mail and Mail on Sunday newspapers.